This should be especially good news for Moderna (NASDAQ: MRNA). The first hurdle is that Moderna must obtain FDA Emergency Use Authorization (EUA) for its omicron booster. The second hurdle for Moderna is to secure an additional supply deal with the U.S. government that includes omicron boosters.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting